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Background
The aim of this study was to compare the long-term safety and efficacy of oral busulfan 12
mg/kg plus melphalan 140 mg/m2 and melphalan 200 mg/m2 as conditioning regimens for
autologous stem cell transplantation in newly diagnosed patients with multiple myeloma in the
GEM2000 study. 
Design and Methods
The first 225 patients received oral busulfan 12 mg/kg plus melphalan 140 mg/m2; because of
a high frequency of veno-occlusive disease, the protocol was amended and a further 542
patients received melphalan 200 mg/m2.
Results
Engraftment and hospitalization times were similar in both groups. Oral busulfan 12 mg/kg
plus melphalan 140 mg/m2 resulted in higher transplant-related mortality (8.4% versus 3.5%;
P=0.002) due to the increased frequency of veno-occlusive disease in this group. Response rates
were similar in both arms. With respective median follow-ups of 72 and 47 months, the median
progression-free survival was significantly longer with busulfan plus melphalan (41 versus 31
months; P=0.009), although survival was similar to that in the melphalan 200 mg/m2 group.
However, access to novel agents as salvage therapy after relapse/progression was significantly
lower for patients receiving busulfan plus melphalan (43%) than for those receiving melphalan
200 mg/m2 (58%; P=0.01). 
Conclusions
Conditioning with oral busulfan 12 mg/kg plus melphalan 140 mg/m2 was associated with
longer progression-free survival but equivalent survival to that achieved with melphalan 200
mg/m2 but this should be counterbalanced against the higher frequency of veno-occlusive dis-
ease-related deaths. This latter fact together with the limited access to novel salvage therapies
in patients conditioned with oral busulfan 12 mg/kg plus melphalan 140 mg/m2 may explain
the absence of a survival difference. Oral busulfan was used in the present study; use of the
intravenous formulation may reduce toxicity and result in greater efficacy, and warrants further
investigation in myeloma patients. (Clinicaltrials.gov identifier: NCT00560053). 
Key words: multiple myeloma, melphalan, oral busulfan, conditioning regimens, autologous
stem cell transplantation, survival, progression-free survival.
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Introduction
In multiple myeloma (MM) patients, the use of high-
dose chemotherapy supported by autologous stem cell
transplantation (HDT/SCT) has led to improvements in
response rate, progression-free survival, and, in some stud-
ies, overall survival compared with the outcomes achieved
with conventional chemotherapy.1,2 Although this treat-
ment approach has been used for over 20 years,3,4 having
become the standard of care for patients under the age of
65–70 years,5,6 research focused on improving the anti-
myeloma efficacy of HDT has been scarce. 
After initial cases described by McElwain and Powles,3
the first standard HDT regimen with SCT support was
reported by the Arkansas Group in 1987, and consisted of
total body irradiation with 850 cGy followed by intra-
venous melphalan 140 mg/m2 (MEL140).7 The second and
most widely accepted regimen was reported in 1992 by
the same group8 and was based on a single dose of mel-
phalan 200 mg/m2 (MEL200). The Intergroupe Francophone
du Myélome (IFM) 9502 randomized trial compared both
regimens and established the latter as the universal stan-
dard conditioning regimen, on the basis that MEL200 was
less toxic and was associated with a trend towards longer
overall survival than MEL140 plus total body irradiation.9
The IFM also explored the value of increasing the dose
of melphalan to 220 mg/m2 for high-risk MM patients but
this resulted in excessive gastrointestinal toxicity and fur-
ther evaluation was abandoned.10,11 Likewise, other HDT
regimens, including busulfan alone,12 busulfan plus either
cyclophosphamide13 or melphalan,14 or combinations of
other drugs15,16 have not progressed into full clinical devel-
opment. More recently, novel drugs, such as bortezomib,
have been incorporated into the conditioning regimens,
but without consolidated results yet.17,18
Nevertheless, some of these HDT regimens may have
potential. Our group published the results of two retro-
spective studies19,20 in which the use of oral busulfan 12
mg/kg plus MEL140 (BUMEL) resulted in a longer median
progression-free survival (30 months) compared with
MEL200 (22 months) or MEL140 plus total body irradia-
tion (20 months). Thus, the Programa Español de
Tratamientos en Hematología (PETHEMA)/ Grupo Español de
Mieloma (GEM) decided to prospectively investigate the
BUMEL conditioning regimen in patients with newly
diagnosed MM in the GEM2000 protocol. However, the
first interim analysis21 revealed a high incidence of hepatic
veno-occlusive disease (VOD) and the protocol was
amended so that MEL200 became the conditioning treat-
ment. 
Here we report the final results of the prospective, non-
randomized GEM2000 study with particular focus on the
impact of receiving either BUMEL or MEL200 condition-
ing. The only difference between the two groups was the
date of study entry; inclusion criteria, initial induction reg-
imen (VBMCP/VBAD), interval from diagnosis to trans-
plant, and planned post-transplant therapy remained iden-
tical across both groups. 
Design and Methods 
Therapeutic program
As outlined previously,22-26 the GEM2000 protocol was active
from January 2000 to February 2005 (ClinicalTrials.gov:
NCT00560053); patients aged less than 70 years with sympto-
matic, newly diagnosed MM who were candidates for HDT/SCT
were included. Patients received induction therapy comprising six
alternating cycles of VBMCP/VBAD chemotherapy, with periph-
eral blood stem cell collection after cycle 4 using granulocyte
colony-stimulating factor 16-24 µg/kg daily for 5 days for priming.
After peripheral blood stem cell collection (target ≥2¥106 CD34+
cells/kg) and two additional cycles of VBMCP/VBAD, patients
underwent their first HDT/SCT.27 Patients failing to achieve com-
plete response or near complete response were offered either a
tandem autologous transplant or a reduced-intensity conditioning
allogeneic transplant if a human leukocyte antigen (HLA)-identical
sibling donor was available. Following HDT/SCT (either single or
tandem), all patients were scheduled to receive 2 years mainte-
nance therapy with interferon (3 MU three times weekly) and
prednisone (50 mg on alternate days). The protocol was approved
by the local research ethics committees of all participating institu-
tions; all patients provided written informed consent. This study is
registered at ClinicalTrials.gov as NCT00560053.
Myeloablative therapy 
The first 225 patients included in the trial received BUMEL (oral
busulfan 1 mg/kg every 8 h on days –6 to –3 [total dose 12mg/kg],
plus melphalan 140 mg/m2 in a single dose on day –2) as condi-
tioning. Following results of the interim analysis performed in June
2002 showing a high incidence of VOD (8%) and a transplant-
related mortality of 8.4%21 BUMEL was stopped and the protocol
was amended from BUMEL to MEL200 as conditioning (melpha-
lan 200 mg/m2 in a single dose on day –2 or in two divided doses
on days –3 and –2). 
Patients
One thousand and seventy-five consecutive patients were
enrolled in GEM2000. One hundred and seventeen (11%) of those
pre-selected were excluded for failing to meet inclusion criteria
(non-secretory MM, age > 75 years, serum creatinine > 2 mg/dL,
or relevant comorbidities). Another 173 (16%) patients who start-
ed chemotherapy did not proceed to transplantation due to pro-
gressive disease followed by death or protocol change (n=68), seri-
ous comorbidity (n=34), patients’ decision (n=31), failure of
peripheral blood stem cell mobilization (n=30), and other reasons
(n=13). Of the 782 patients eventually transplanted, nine were
excluded from the final analysis because SCT was performed with
bone marrow (n=1), bone marrow plus peripheral blood stem cells
(n= 1) or purged peripheral blood stem cells (n= 7); other cases
could not be evaluated (n=7) because of insufficient or inconsistent
data. Therefore, for this study 767 patients were evaluable: 225
treated with BUMEL and 542 with MEL200.
End-points
Time to granulocyte recovery was defined as the number of
days from infusion until a neutrophil count of greater than
0.5¥109/L was reached. Time to platelet recovery was defined as
the number of days from infusion to the first of 7 consecutive days
with a platelet count greater than 20¥109/L. The time between
peripheral blood stem cell infusion and discharge was considered
the hospitalization time. Transplantation-related mortality was
defined as any death occurring within 100 days after infusion of
the peripheral blood stem cells (limit not applied in cases of VOD
because of the singularly late onset of this complication),21 exclud-
ing those deaths that could be directly attributed to disease pro-
gression. Toxicity was recorded according to the Seattle regimen-
related toxicity grading28 and the diagnosis of VOD was estab-
lished using both the Seattle29 and Baltimore30 criteria.
Disease response was assessed post-induction and 90 days post-
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transplant using European Group for Blood and Marrow
Transplantation (EBMT) criteria,31 modified to include near com-
plete response. The reference M-protein level for each patient was
that recorded at initiation of induction therapy. 
In each conditioning group, overall survival and progression-free
survival were assessed from the time of transplantation.
Progression-free survival was measured until progression, relapse,
or death. Patients who had not progressed or relapsed were cen-
sored on the last date they were known to be alive and event-free.
Overall survival was calculated until date of death or last visit.
Statistical analysis
All statistical analyses were performed using Statistica 7.0 soft-
ware (StatSoft Inc., Tulsa, OK, USA). For univariate analysis, sur-
vival curves were calculated according to the Kaplan-Meier
method and differences were evaluated using a log-rank test. P
values less than 0.05 were considered to indicate a statistically sig-
nificant difference. Multivariate analysis was performed using an
adjusted Cox proportional-hazards regression model. After step-
wise regression analysis (all prognostic factors shown in Table 1
were initially included), the variables selected for the progression-
free survival model were: hemoglobin of 10 g/dL or less,
International Staging System (ISS) disease stage,32 pre- and post-
HDT/SCT response status (χ2 P from 0.0002 to <10-6); for the over-
all survival model, the variables selected were hemoglobin of
10g/dL or less, Eastern Cooperative Oncology Group performance
status at diagnosis, lactate dehydrogenase above the normal limit,
and pre-/post-HDT/ASCT response status (χ2 P from 0.002 to <10-
6). The χ2 and Fisher's exact two-sided tests were used for compar-
isons between categorical variables and the Wilcoxon rank-sum or
t-test was used for continuous variables.
Results
Patients
The flow of patients through the study protocol is
shown in Figure 1. In total, 767 patients received at least
one HDT/SCT and were included in this analysis: 225
received BUMEL and 542 received MEL200 conditioning.
Overall, 332 patients achieved either partial response,
minor response or stable disease after their first HDT/SCT
and, per protocol, were candidates for a second transplant;
however, 190 did not proceed, mainly due to the patients’
refusal. The median follow-up was 48 months.
Patients in both conditioning groups had similar disease
characteristics at diagnosis (Table 1). In the BUMEL group,
patients were slightly younger (median age 56 versus 58
years, P=0.002), and the frequency of patients who under-
went tandem transplantation was higher (54 versus 35%,
P=0.001) than in the MEL200 group. As shown in Table 1,
times from diagnosis to SCT and response status before
HDT/SCT were not significantly different between
groups.
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Table 1. Characteristics of patients at diagnosis, tandem transplantation frequency and disease status prior to transplantation according to con-
ditioning regimen.
                                                                             BUMEL N=225                                                                            MEL200 N=542
                                                                               At diagnosis                                                                                 At diagnosis
Sex ( male), %                                                                             46                                                                                                                      45
Age, years                                                                          56 (55–57, ±8)                                                                                             58 (57–59, ±8)*
M-protein (IgG/ IgA/ light chain), %                                 52/ 26/ 22                                                                                                         56/ 27/ 17
Performance status (ECOG), <2 / 2, %                              58/ 42                                                                                                               58/ 42
ISS Stage I / II / III, %                                                           37/ 43/ 20                                                                                                         34/ 48/ 18
Time from diagnosis to ASCT, months                     9.5 (9.2–9.7 ±2.1)                                                                                          9.8 (9.6–10 ±2.6)
CD34+ cells/kg infused                                                 3.1 (2.9–3.4 ±1.7)                                                                                        3.05 (2.9–3.1 ±1.5)
Tandem transplantation in 
non-nCR/CR patients, %                                                             54                                                                                                                     35*
                                                           At diagnosis                         At transplantation                        At diagnosis At transplantation
Creatinine, mg/dL                                   1.2 (1.1–1.4, ±1)                           0.8 (0.8–0.9, ±0.3)                         1.2 (1.1–1.3, ±0.8) 0.9 (0.9–1, ±0.6)
Albumin, g/dL                                         3.7 (3.4–3.9, ±1.7)                          3.7 (3.6–3.8, ±0.5)                         3.6 (3.4–3.7, ±1.6) 4 (3.8–4.2, ±2.6)
Albumin ≥ 3.5 g/dL                                               55                                                       71                                                       55 75
Calcium, mg/dL                                     9.8 (9.6–10.1, ±1.7)                          9 (8.9–9.1, ±0.8)                         9.8 (9.5–10.2, ±1.8) 9 (8.9–9.1, ±0.8)
Calcium, >10 mg/dL                                            35                                                        7                                                        29 8
Hemoglobin, g/dL                               10.5 (10.2–10.8, ±2.3)                    11.6 (11.4–11.8, ±1.5)                  11.1 (10.8–11.1, ±2.1)* 12 (11.9–12.1, ±1.5)
Hemoglobin, £ 10 g/dL                                       41                                                       12                                                       33 7
β2 microglobulin, mg/L                        3.4 (3.1–3.7, ±1.9)                          2.3 (2.1–2.5, ±1.3)                         3.4 (3.2–3.5, ±1.9) 2.3 (2.2–2.4, ±1.1)
β2 microglobulin ≥ 3.5 mg/L                             34                                                       11                                                       32 12
LDH > normal limit                                             12                                                       12                                                       13 12
Response status pre-HDT/SCT:
PD/ SD/ PR                                                               -                                                4.8/ 13.7/ 55                                               - 4.7/ 13/ 57.7
Response  status pre--HDT/SCT: nCR/ CR      -                                                   13.7/ 12.8                                                  - 12/ 12.6
Mean values (CI 95%, ± SD) are given for continuous variables, or percentage of patients with that characteristic. *Statistically significant differences. BUMEL: 12 mg/kg, plus mel-
phalan at 140 mg/m2; MEL200 200 mg/m2 melphalan. HDT/SCT: high dose chemotherapy and stem cell support; ISS: International Staging System; ASCT: autologous stem cell
transplantation; nCR: near complete response; CR: complete response; PD: progressive disease; SD: stable disease; PR: partial response; LDH: lactate dehydrogenase.
Hematologic recovery and hospitalization time
The number of CD34+ cells infused did not differ
between the two conditioning groups (Table 1); no cases
of graft failure were reported. In patients receiving growth
factors (BUMEL 91%, MEL200 94%), no differences were
observed between the BUMEL and MEL200 groups in
mean time to granulocyte recovery (11.6, [95% confidence
interval (CI): 11.1–12.1±3.4] versus 11.8 [11.5–12±2.9]
days; P=0.4), mean time to platelet engraftment (14.0
[12.2–15.8±12.7] versus 16.2 [13.7–18.8±29.2] days; P=0.2),
or mean hospitalization time (19.7 [18.5–20.9±8.2] versus
20.6 [17.7–23.6±33.6] days; P=0.7). Similar results were
observed in patients who did not receive growth factors
(no statistically significant differences).
Non-hematologic adverse effects and transplant-relat-
ed mortality
The overall incidence of organ toxicity associated with
HDT was 72% (162 patients) with BUMEL and 69% (373
patients) with MEL200 (P=0.4). As shown in Table 2, the
most relevant adverse effects were stomatitis, gastroin-
testinal toxicity and hepatotoxicity. One patient died from
sudden arrhythmia and another from heart failure; these
were reported as MEL200-related toxicities. Fever was
reported in 168 (75%) and 386 (71%) patients in the
BUMEL and MEL200 groups, respectively (P=0.2), pre-
dominantly associated with neutropenia. The frequency
of bacteremia or other microbiological events was also
similar between the two conditioning groups (BUMEL
31%, MEL200 27%; P=0.2). 
With regards to VOD, 19 patients (8%) who received
BUMEL compared with only two patients (0.4%) who
received MEL200 had this complication (P<0.00001), as
previously reported.21 Mortality was directly related to
VOD in seven (3%) patients in the BUMEL group and in
one (0.2%) patient in the MEL200 group (P=0.003). In
addition, 12 patients (5.3%) treated with BUMEL died
within 100 days of SCT from causes other than MM (9
septic complications, 1 intracranial hemorrhage, 1
ischemic central nervous system stroke, 1 cause
unknown), compared with 16 patients (2.9%) in the
MEL200 group (13 sepsis, 1 CNS hemorrhage, 1 engraft-
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Table 2. Non-hematologic toxicity (excluding VOD) due to high-dose regimens.
Grade I Grade II Grade III Grade IV*
BUMEL MEL200 BUMEL MEL200 BUMEL MEL200 BUMEL MEL200 II/III differences
n (%) P
Cardiac 2 (0.8) 2 (0.3) 3 (1.3) 8 (1.4) – 7 (1.2) – 2 (0.3) 0.2
Renal – 2 (0.3) 3 (1.3) 8 (1.4) 3 (1.3) 3 (0.5) – – 0.2
Pulmonary – 1 (0.1) 1 (0.4) 2 (0.3) 1 (0.1) 3 (0.5) – – 0.6
Hepatic 10 (4.4) 9 (1.6) 6 (2.6) 1 (0.1) 1 (0.1) – – – 0.0004
Central nervous – 1(0.1) 2 (0.8) 5 (0.9) – 1 (0.1) – – 0.7system
Stomatitis 19 (8.4) 53 (9.7) 73 (32.4) 141 (26.0) 21 (9.3) 34 (6.7) – – 0.01
Gastrointestinal 5 (2.2) 45 (8.3) 10 (4.4) 34 (6.7) 2 (0.8) 11 (2.0) – – 0.09
*Fatal toxicity. VOD:  veno-occlusive disease; BUMEL:  oral busulfan 1 mg/kg/8 h plus melphalan 140 mg/m2; MEL200:  200 mg/m2.
Figure 1. Patient flow
through the GEM2000
study protocol for the
767 patients included
in this analysis, includ-
ing salvage treatment
received in patients
who relapsed/pro-
gressed.
ment syndrome, 1 suicide). The overall transplant-related
mortality rate was 8.4% (19 patients) and 3.5% (19
patients) in the BUMEL and MEL200 groups, respectively
(P=0.002). Excluding VOD, this difference was not statis-
tically significant (P=0.1).
Post-transplant responses 
Post-transplant responses were equivalent in evaluable
patients who received BUMEL (n=208) and MEL200
(n=529): 38% complete response, 13% near complete
response, 39% partial response, 6% stable disease, 3%
progressive disease, and 36% complete response, 17%
near complete response; 39% partial response, 5% stable
disease, 4% progressive disease, respectively (P=0.9 to
0.1). In addition, there were no statistically significant dif-
ferences in the rates of improvement in response between
the conditioning regimens when patients were stratified
by pre-HDT/SCT status (data not shown).
Survival analyses
Progression-free survival
After a median follow-up of 72 and 47 months, respec-
tively, the median progression-free survival was 41
months for patients who received BUMEL and 31 months
for those who received MEL200. At 5 years, 39% (88
patients, 95% CI: 34–44%) of patients in the BUMEL
group remained progression-free compared to 21% (114
patients, 95% CI: 18–24%) in the MEL200 group
(P=0.009; Figure 2A). A similar pattern was observed
when tandem transplant patients were excluded (P=0.002;
Figure 2B) or when only patients with complete response
(P=0.02; Figure 2C) or less than complete response
(P=0.02; Figure 2D) as their post-transplant response were
considered.
Overall survival
Patients treated with BUMEL or MEL200 had similar
overall survival; the median overall survival was 79 and 71
months, and 5-year rates were 55% (124 patients, 95% CI:
45–60%) and 57% (309 patients, 95% CI: 54–60%),
respectively (Figure 3). No differences between the
BUMEL and MEL200 groups in median overall survival
were observed when patients who received a tandem
transplant were excluded (77 versus 70 months, P=0.4),
when the analysis focused on those patients achieving
complete response after transplant (82 months versus not
reached, P=0.3), or when only patients who did not
achieve complete response were analyzed (64 versus 63
months, P=0.5)
Influence of salvage therapy on survival
At data cut-off, 99 (44%) and 267 (49%) patients in the
BUMEL and MEL200 groups, respectively, had received
salvage therapy (Figure 1). The different periods of recruit-
ment for patients in the BUMEL (2000–2002) and MEL200
(2002–2005) groups resulted in disparate access to rescue
therapies at relapse/progression. Among patients who
received salvage therapy in the BUMEL and MEL200
groups, 37% and 24%, respectively, received conventional
Melphalan versus busulfan-melphalan in HDT/SCT for MM
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Figure 3. Overall survival according to conditioning regimen.
Figure 2. Progression-
free survival according
to conditioning regimen
among (A) all patients;
(B) all patients excluding
those treated with autol-
ogous or allogeneic tan-
dem transplantation; (C)
only patients achieving
complete response after
HDT/SCT; (D) patients
achieving less than com-
plete response after
HDT/SCT.
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treatments such as chemotherapy or corticosteroids
(P=0.01). In contrast, 43% and 58% of patients in the
BUMEL and MEL200 groups, respectively, received borte-
zomib and/or thalidomide-based combinations as salvage
therapy (P=0.01). A second HDT/SCT was used as first-
line rescue treatment in 7% and 8% (P=0.8) of patients in
the BUMEL and MEL200 groups, respectively. At data cut-
off, 13% and 10% of patients in the BUMEL and MEL200
groups, respectively (P=0.4), had biological relapses but
had not yet received salvage treatment.
Regardless of conditioning regimen, among patients
who had relapsed/progressed, overall survival was signifi-
cantly longer in patients who received thalidomide and/or
bortezomib-based salvage therapy (5-year overall survival
rate: 38%) than in patients who did not (5-year overall sur-
vival rate: 13%; P<0.0001) 
Finally, an adjusted multivariate analysis for overall sur-
vival was performed in relapsing patients (Cox model χ2
31.8, P=0.00004) and it was found that both use of
thalidomide or bortezomib as salvage therapy (OR 2.2,
P=0.000001) and BUMEL (OR 1.4, P=0.04) as the condi-
tioning regimen showed independent positive prognostic
influence on disease outcome with respect to use of
chemotherapy or corticosteroids at relapse/progression
(OR 0.4) or MEL200 (OR 0.7) as the conditioning regimen.
Discussion
The use of HDT followed by stem cell support is a stan-
dard of care for young, newly diagnosed MM patients33
and MEL200 has become the undisputed standard condi-
tioning regimen. Research into improving HDT/SCT effi-
cacy using agents such as cyclophosphamide, thiotepa,
BCNU, dacarbacine, idarubicin or etoposide has so far
proved inconclusive.16,34-37 Only BUMEL has been associat-
ed with some benefit compared with MEL200, although
the studies had limited power to demonstrate a differ-
ence.19,20,38 Recently the IFM group reported on the efficacy
of adding bortezomib to MEL200 as part of the condition-
ing regimen, resulting in a significant increase in complete
response rate as compared to that with only MEL200 in a
matched control historical comparison ( 35% versus 11%
complete responses, respectively).17
Based on the findings of two retrospective GEM studies
showing higher complete response rates and longer, albeit
not statistically significantly, so, event-free survival and
overall survival with BUMEL than with MEL200, BUMEL
was selected as the initial conditioning regimen in
GEM2000. However, after an interim analysis21 demon-
strating a high incidence of late VOD (8%) with an unusu-
ally high mortality (8.4%), BUMEL was replaced by
MEL200. After this protocol amendment the incidence of
VOD fell to 0.4%. The erratic pharmacokinetics of oral
busulfan39 and the altered clearance of melphalan caused
by the depletion of intracellular glutathione, induced by
busulfan,40-42 may have caused this complication. Some
studies have shown that adjusting the oral busulfan dose
according to plasma levels may lead to a reduction in the
frequency of VOD.43
An alternative to oral busulfan is intravenous busulfan,
which results in more stable plasma levels.44 Use of high
dose intravenous busulfan in combination with
cyclophosphamide and other drugs in the context of autol-
ogous or allogeneic transplantation for acute leukemia and
non-Hodgkin’s lymphoma has drastically reduced the
incidence of VOD while maintaining efficacy.39 In a recent
Spanish phase II pilot study45 including both relapsed and
newly diagnosed MM patients, none of the patients given
intravenous BUMEL/SCT developed VOD and the com-
plete/near complete response rate post-transplant was
49%. The possibility of maintaining efficacy with intra-
venous busulfan while reducing or eliminating VOD
renewed our interest in the GEM2000 results, presented
herein after a median follow-up of 48 months.
In GEM2000, when patients with VOD were excluded,
there were no differences between BUMEL and MEL200
regarding engraftment and duration of hospitalization –
the only significant differences were in the incidences of
stomatitis and hepatotoxicity. It is doubtful that these dif-
ferences are of clinical significance: the frequency of grade
III stomatitis was 9.3% with BUMEL and 6.7% with
MEL200, and only one of 225 patients treated with
BUMEL had grade III hepatotoxicity other than VOD. In
contrast, two patients receiving MEL200 died from car-
diotoxicity.
In terms of efficacy, the most relevant finding in this
analysis was the longer progression-free survival seen in
the BUMEL group (median 41 months) compared with the
MEL200 group (31 months), an improvement that persist-
ed even when tandem transplantation patients were
excluded. This effect was not detected in an earlier analy-
sis46 as the PFS curves overlapped for first 24 months and
only separated after this point. Because response rates
were similar with both regimens and the advantage of
BUMEL over MEL200 was maintained in patients achiev-
ing complete response or less than complete response, it
can be concluded that the difference in progression-free
survival is, in part, either independent of the depth of the
response or that the conventional methods used for com-
plete response assessment were not sensitive enough to
detect deep responses.25 Alternatively, combining alkylat-
ing agents might target dormant tumor cells, including
tumor stem cells, more specifically, thus impeding or
delaying tumor progression resulting from this ‘pharmaco-
logic sanctuary’.47
The advantage in progression-free survival seen with
BUMEL did not extend to overall survival. One possible
explanation is that overall survival in MM is dependent on
the effects of subsequent lines of therapy as salvage treat-
ment and thus the value of overall survival as an end-point
in MM is questionable. Of note, in the GEM2000 study,
BUMEL conditioning was given between 2000 and 2002
with patients being switched to MEL200 after 2002. These
differences in dates explain why the access to novel agents
as treatments for relapse/progression was less frequent in
patients previously treated with BUMEL than in those
treated with MEL200. This disparity in our study, as
observed in other studies,48 may have had a significant
impact on overall survival. Although in our study patients
receiving thalidomide or bortezomib at the time of relapse
had a significantly longer overall survival than that of
patients rescued with conventional chemotherapy this
comparison should be qualified with the caveat that
patients had to live longer to get to the novel agent thera-
pies and that by itself would put those patients who man-
aged to do so in a better position in terms of disease biol-
ogy. Nevertheless, in the multivariate analysis it was
found that both the conditioning regimen (BUMEL versus
MEL200) and the type of rescue therapy (novel agents ver-
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sus conventional chemotherapy) were independent prog-
nostic factors for overall survival in relapsing patients.
While the study has limitations due to its sequential
nature, other study characteristics such as its prospective
nature, large sample size, length of follow-up, and homo-
geneity of inclusion criteria, and induction and post-trans-
plantation treatments, clearly contribute positively to the
value of this work. Thus, in conclusion, despite the effects
of possible confounding factors, the results of our analysis
suggest that BUMEL may have greater anti-myeloma
activity than MEL200; however, this should be balanced
against its higher toxicity profile and transplant-related
mortality, at least with the oral formulation of busulfan.
Taken together, our data support a future phase III study
comparing intravenous BUMEL to MEL200 in the context
of autologous transplantation as first-line treatment for
young MM patients.
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